Aclaris Therapeutics (ACRS) Bank of America Global Healthcare Conference 2026 summary

Strategic Focus and Innovation

• Emphasizing innovation in immunological assets for dermatologic, respiratory, and I&I diseases, targeting validated pathways with both large and small molecule therapeutics.

• Portfolio includes best-in-class bispecifics and oral ITK inhibitors, aiming for high efficacy and extended dosing intervals.

• State-of-the-art kinase biology research platform supports pipeline development.

• Notable for combining large and small molecule expertise in a smid-cap setting.

• Focus on advancing three novel compounds through clinical programs, with an additional IND expected in 2026.

Market Opportunity and Commercial Strategy

• Over 1 billion people globally live with addressable immunology and inflammation diseases, including atopic dermatitis, alopecia areata, vitiligo, lichen planus, asthma, and COPD.

• Significant unmet need and opportunity for innovative therapeutics in Th1, Th2, and Th17-mediated diseases.

• Lichen planus identified as an orphan indication with no approved therapies, offering potential for accelerated regulatory pathway and premium pricing.

• Dual approach targets both oral therapies and biologics to address gaps in efficacy, safety, and convenience.

• Cash runway extends through 2028, with $191 million on hand as of March 2026, supporting all planned clinical catalysts.

Pipeline Highlights and Clinical Development

• Bosakitug (anti-TSLP mAb/ATI-045) and ATI-052 are advanced TSLP-targeting biologics with extended residence time and potential best-in-class profiles.

• ATI-052 is a bispecific antibody targeting TSLP and IL-4Rα, showing greater potency than combinations of existing mAbs.

• ATI-2138 is an oral ITK/JAK3 inhibitor with a unique mechanism, demonstrating strong efficacy and safety in atopic dermatitis and advancing to lichen planus trials.

• Next-generation ITK inhibitors and bispecific antibodies are in preclinical or IND-enabling stages, with INDs planned for 2026–2027.

• Multiple phase I-B and II-B studies ongoing or planned in severe atopic dermatitis, asthma, and lichen planus.